Metabolic disease drugs
For fiscal 2017, Alexion Pharmaceuticals (ALXN) has projected its metabolic disease franchise to earn revenues in the range of $375 million–$400 million. The company expects a moderate rise in patient demand for its metabolic disease drugs in early 2017 as a large number of eligible patients have already started Strensiq therapy in 2016.
Alexion Pharmaceuticals also expects to earn reduced Strensiq revenues on a per-patient basis as the company anticipates pricing pressures in 2017. In 2017, Alexion Pharmaceuticals expects demand for Strensiq to arise from younger HPP (hypophosphatasia) patients, while more adult patients commenced therapy in 2016.
Within one year of its launch, Strensiq managed to capture a significant portion of the HPP market due to Alexion’s continued focus on creating disease awareness and educating physicians and patients about diagnostic tests. These efforts culminated into the company identifying target HPP patients even before Strensiq was approved for the indication by the US Food and Drug Administration.
With Alexion steadily identifying new HPP patients, including those adults who have suffered from pediatric-onset HPP, Strensiq is expected to prove to be a major growth driver for the company in 2017. The company also expects demand from patients to rise as the company succeeds in securing access for Strensiq in multiple European markets. (For more on Strensiq, please refer to Market Realist’s Strensiq Boosted Alexion Pharmaceuticals’ Revenues in 2016.)
Notably, Alexion Pharmaceuticals makes up about 0.14% the iShares Core S&P 500 ETF’s (IVV) total portfolio holdings.
Continue to the next part of this series for a closer look at Alexion Pharmaceuticals’ research programs.